Rifampicin reduces α-synuclein in a transgenic mouse model of multiple system atrophy

NeuroReport

Volumn 19, Issue 13, 2008, Pages 1271-1276

  Ubhi, Kiren ^a   Rockenstein, Edward ^a   Mante, Michael ^a   Patrick, Christina ^a   Adame, Anthony ^a   Thukral, Monica ^a   Shults, Clifford ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Astrogliosis; Dendrites; Oligodendrocytes; Protein aggregation; Synucleopathy

Indexed keywords

ALPHA SYNUCLEIN; MONOMER; OLIGOMER; RIFAMPICIN; BETA SYNUCLEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SHY DRAGER SYNDROME; TRANSGENIC MOUSE; ANIMAL; CELL INCLUSION; CONFOCAL MICROSCOPY; DRUG EFFECT; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; OLIGODENDROGLIA; PATHOLOGY; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; BETA-SYNUCLEIN; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; INJECTIONS, INTRAPERITONEAL; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MULTIPLE SYSTEM ATROPHY; NERVE DEGENERATION; OLIGODENDROGLIA; RIFAMPIN; SYNUCLEINS;

EID: 52649175462     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32830b3661     Document Type: Article

References (18)

1. Beyer K, Ariza A. Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J Neuropathol Exp Neurol 2007; 66:965-974.
2. Wakabayashi K, Takahashi H. Cellular pathology in multiple system atrophy. Neuropathology 2006; 26:338-345.
3. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 2007; 27:484-493.
4. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, et al. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett 1998; 440:71-75.
5. Batelli S, Albani D, Rametta R, Polito L, Prato F, Pesaresi M, et al. DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS ONE 2008; 3:e1884.
6. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7:97-109.
7. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000; 157:401-410.
8. Windisch M, Wolf HJ, Hutter-Paier B, Wronski R. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders? Curr Alzheimer Res 2007; 4:556-561.
9. Li J, Zhu M, Rajamani S, Uversky VN, Fink AL. Rifampicin inhibits alphasynuclein fibrillation and disaggregates fibrils. Chem Biol 2004; 11:1513-1521.
10. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 2006; 97:105-115.
11. Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 2005; 25: 10689-10699.
12. Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L. Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. J Biol Chem 1995; 270:28257-28267.
13. Mindermann T, Landolt H, Zimmerli W, Rajacic Z, Gratzl O. Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J Antimicrob Chemother 1993; 31:731-737.
14. Mindermann T, Zimmerli W, Gratzl O. Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother 1998; 42:2626-2629.
15. Yulug B, Kilic U, Kilic E, Bahr M. Rifampicin attenuates brain damage in focal ischemia. Brain Res 2004; 996:76-80.
16. Kuczenski R, Everall IP, Crews L, Adame A, Grant I, Masliah E. Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp Neurol 2007; 207:42-51.
17. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005; 8:657-663.
18. Ono K, Hirohata M, Yamada M. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro. J Neurosci Res 2007; 85:1547-1557.